应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

Znn3bq.jpeg
小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 临床研究 » 求Ibrutinib 一个Ⅲ期临床试验和试验数据、结果
北京石油化工学院2026年研究生招生接收调剂公告
172/2返回列表上一页12
查看: 2070  |  回复: 16
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看

kdl0721

金虫 (著名写手)
引用回帖:
10楼: Originally posted by xiaoerduomao at 2014-04-09 09:50:28
这个3期临床还没结束呢，按照你给的是ongoing，并不是completed
http://scimore.asia:1080/pharmallPluswebsite/database/tpharma/cortallis/ibrutinib001755.htm

谢谢，这个三期临床试验由于结果呈显著阳性已经被FDA审查机构统一结束了，数据还没有公布，可能要到2014年ASCO年会上。你这个是汤森路透的数据？
赞一下 回复此楼
11楼2014-04-09 11:13:19
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

xiaoerduomao

金虫 (小有名气)
引用回帖:
11楼: Originally posted by kdl0721 at 2014-04-09 11:13:19
谢谢，这个三期临床试验由于结果呈显著阳性已经被FDA审查机构统一结束了，数据还没有公布，可能要到2014年ASCO年会上。你这个是汤森路透的数据？...

是的
回复此楼
12楼2014-04-09 11:36:52
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

dengchun14
13楼2014-04-09 11:43:16
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
看来都没有知道该临床试验具体数据的，只能等2014ASCO年会了。
赞一下 回复此楼
14楼2014-04-09 13:36:44
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
引用回帖:
12楼: Originally posted by xiaoerduomao at 2014-04-09 11:36:52
是的...

能给我发一份最新完整版的汤森路透报告吗？谢谢，金币都给你。
赞一下 回复此楼
15楼2014-04-09 13:39:23
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

kdl0721

金虫 (著名写手)
版主，请关闭该求助帖子，我已得到结果，谢谢！
赞一下(1人) 回复此楼
16楼2014-06-06 10:38:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

tsenghw

铁虫 (初入文坛)

【答案】应助回帖

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.
Collaborators (67)

Abstract
BACKGROUND:
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.

METHODS:
In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.

RESULTS:
At a median follow-up of 9.4 months, ibrutinib significantly improved progression-free survival; the median duration was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group (hazard ratio for progression or death in the ibrutinib group, 0.22; P<0.001). Ibrutinib also significantly improved overall survival (hazard ratio for death, 0.43; P=0.005). At 12 months, the overall survival rate was 90% in the ibrutinib group and 81% in the ofatumumab group. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% vs. 4.1%, P<0.001). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. Similar effects were observed regardless of whether patients had a chromosome 17p13.1 deletion or resistance to purine analogues. The most frequent nonhematologic adverse events were diarrhea, fatigue, pyrexia, and nausea in the ibrutinib group and fatigue, infusion-related reactions, and cough in the ofatumumab group.

CONCLUSIONS:
Ibrutinib, as compared with ofatumumab, significantly improved progression-free survival, overall survival, and response rate among patients with previously treated CLL or SLL. (Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.).
赞一下 回复此楼
17楼2015-11-11 22:17:53
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 kdl0721 的主题更新
172/2返回列表上一页12
普通表情 龙 兔 虎 猫
最具人气热帖推荐 [查看全部] 作者 回/看 最后发表
[考研] 388求调剂 +4 四川王涛 2026-04-07 6/300 2026-04-07 18:29 by ?丶丶丶
[考研] 307求调剂 +11 超级伊昂大王 2026-04-06 11/550 2026-04-07 11:54 by dongzh2009
[考研] 求调剂 一志愿西南交通大学085701环境工程 282分 +13 多多爱吃汉堡 2026-04-04 14/700 2026-04-07 11:22 by 诗与自由
[考研] 308求调剂 +11 墨墨漠 2026-04-06 11/550 2026-04-06 22:56 by 875465
[考研] 327求调剂 +5 Xxjc1107. 2026-04-06 5/250 2026-04-06 21:43 by dongzh2009
[考研] 338求调剂 +4 我想上岸ii 2026-04-05 4/200 2026-04-06 21:04 by 木子君1218
[考研] 一志愿北交大材料工程总分358求调剂 +10 cs0106 2026-04-05 12/600 2026-04-06 19:41 by 无际的草原
[考研] 362求调剂一志愿中国石油大学 +4 我要考大 2026-04-06 6/300 2026-04-06 14:11 by 无际的草原
[考研] 一志愿河北工业大学材料工程，初试344求专硕调剂 +6 15933906766 2026-04-05 6/300 2026-04-06 13:21 by 无际的草原
[考研] 材料334求调剂 +19 Eecho# 2026-04-03 19/950 2026-04-06 08:37 by 小小树2024
[考研] 377求调剂 +6 by.ovo 2026-04-05 6/300 2026-04-05 22:18 by dongzh2009
[考研] 298求调剂 +3 manman511 2026-04-05 3/150 2026-04-05 18:09 by kk112233
[考研] 312求调剂 +3 Say Never 2026-04-04 3/150 2026-04-05 11:19 by guoweigw
[考研] 求调剂 +6 朔朔话 2026-04-02 7/350 2026-04-04 19:16 by 蓝云思雨
[考研] 求材料调剂，一志愿郑州大学289分 +15 硕星赴 2026-04-03 15/750 2026-04-04 01:01 by userper
[考研] 一志愿深大085601材料工程专业（专硕）300分可以调剂去哪 +8 10160315 2026-04-02 8/400 2026-04-03 09:36 by hypershenger
[考研] 372分材料与化工（085600）一志愿湖南大学求调剂 +5 蓝笺片 2026-04-02 6/300 2026-04-02 21:37 by dongzh2009
[考研] 318求调剂，计算材料方向 +10 吸喵有害笙命 2026-04-01 11/550 2026-04-02 16:29 by oooqiao
[考研] 考研调剂 +12 Amber00 2026-03-31 12/600 2026-04-02 09:04 by sanrepian
[考研] 江苏科技大学招材料研究生 +4 Su032713. 2026-04-01 5/250 2026-04-01 22:03 by cccchenso
信息提示
关闭
请填处理意见
关闭